Skip to content

Short-Term Changes in Children’s Eye Size with Cyan (Blue-Green) Light: A Short Trial

Short-Term Changes in Ocular Biometry with Cyan Light in Children: A Randomised Pilot Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12626000663358
Enrollment
20
Registered
2026-06-04
Start date
2026-07-01
Completion date
2026-09-30
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to investigate whether wearing cyan (blue-green) light-emitting glasses can produce short-term changes in eye structure in children with myopia, specifically by reducing eyeball length and increasing the thickness of the choroid (an inner layer of the eye). These two measurements are well-established biomarkers of myopia, meaning they are predictable changes used to monitor the effects of myopia control treatments. The trial will compare two interventions: wearing the cyan light glasses over regular single-vision spectacles versus wearing single-vision spectacles alone. Each intervention will last 4 weeks, with a one-week break in between. The study will measure eyeball length and choroidal thickness, and will also monitor participants’ comfort, safety, and the impact on daily activities. We hypothesise that cyan light exposure may lead to measurable changes in these eye parameters compared with standard spectacles alone, helping to inform future strategies for myopia control.

Interventions

What is the intervention? The intervention consists of single-vision spectacles (SVS, control treatment) and cyan light exposure (Cyan+SVS, treatment intervention) delivered via custom-designed cyan light-emitting glasses worn over the participant’s habitual single-vision spectacle (SVS) correction. This light emitting glasses were developed and validated by Chakraborty et al. (2024) in collaboration with EssilorLuxottica (Paris, France), and are designed to emit controlled cyan wavelength light

What is the intervention? The intervention consists of single-vision spectacles (SVS, control treatment) and cyan light exposure (Cyan+SVS, treatment intervention) delivered via custom-designed cyan light-emitting glasses worn over the participant’s habitual single-vision spectacle (SVS) correction. This light emitting glasses were developed and validated by Chakraborty et al. (2024) in collaboration with EssilorLuxottica (Paris, France), and are designed to emit controlled cyan wavelength light (peak wavelength 500 nm, a total average irradiance of 3.0W/m² and maximum irradiance 3.10 W/m²) for ocular stimulation. Who delivers it and their relevant expertise? The intervention is self-administered by participants at home, under the supervision of their caregivers/parents. Participants and caregivers will receive standardised instructions and training from the research team, who have expertise in vision science, clinical research, and paediatric eye studies. How is it delivered? Treatment Intervention: This intervention is delivered through wearable cyan light-emitting glasses, which participants will wear at home during scheduled sessions. The glasses are worn over the participant’s habitual single-vision spectacle (SVS) correction (if applicable) while engaging in normal indoor activities. Control treatment: The control condition is delivered through single-vision spectacles (SVS). Participants will be instructed to wear SVS during all waking hours (except during sleep or water-based activities), seven days per week, for a period of 4 weeks, and to avoid using any other forms of optical correction, including sunglasses. How often and for how long? Treatment intervention: Participants will be instructed to wear the glasses for two 20-minute sessions per day (total daily exposure: 40 minutes): One session in the morning (7:00–11:00 am) and another session in the afternoon (1:00–6:00 pm). The two sessions must be separated by at least 3 hours. This regimen will be followed daily (7 days per week) for 4 weeks. Control treatment: Participants will be instructed to wear SVS during all waking hours (except during sleep or water-based activities), seven days per week, for a period of 4 weeks, and to avoid using any other forms of optical correction, including sunglasses. Washout period: Participants will be randomly assigned to receive either treatment intervention or control intervention during the first four weeks of the study. After completing the first intervention period (weeks 1 through 4), participants will undergo a one-week washout period (week 5), after which they will undergo baseline measurements and cross over to the alternate intervention (weeks 6 through 9). Where is it delivered? The intervention is delivered at the participant’s home environment, allowing use during routine indoor activities. Adherence Adherence will be monitored using a daily logbook completed by participants and their caregivers, documenting each session of light exposure. These records will be reviewed by the research team to monitor compliance with the intervention protocol, identify any missed sessions or deviations and support ongoing safety monitoring throughout the study.

Sponsors

EssilorLuxottica
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
7 Years to 14 Years
Healthy volunteers
No

Inclusion criteria

Participants will be eligible if they meet the following criteria: -Children with myopia, defined as a spherical equivalent refractive error between -0.50 D and -6.00 D -Currently wearing single-vision distance (SVD) spectacles -Astigmatism: less than or equal to -1.25 dioptres cylinder (DC) -Interocular difference in refractive error less than or equal to 1.00 D -Best-corrected visual acuity (BCVA) of 0.00 logMAR or better

Exclusion criteria

Participants will be excluded if they have: -A history of myopia control treatment (e.g., atropine or other interventions) within the past 12 months -A history of significant ocular injury or ocular surgery -Strabismus or other ocular motility disorders -Refractive error other than myopia -Any major systemic disease -Photosensitivity (sensitivity to bright light) -A history of seizures -Wear blue-light filtering lenses or photochromic single-vision spectacles

Outcome results

None listed

Source: ANZCTR · Data processed: Jun 11, 2026